The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

The Laser Therapy Devices market is expected to reach approximately USD 3.6 billion in 2025 and expand to around USD 8.3 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.8% over ...

One of UK's leading pain specialists is today raising the alarm as research reveals that 1 in 3 adults in London being treated for depression are living with undiagnosed chronic pain, often ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the ...

Patient 418, who had tested negative for SARS-CoV-2 four times on August 4, 10, 11 and 12, died on August 12 due to complications of chronic renal failure at the Hue Central Hospi ...

A trial of an interactive game that trains people to alter their brain waves has shown promise as a treatment for nerve pain ...

The following is a summary of “Neuropathic Pain in Nursing Homes,” published in the May 2025 issue of European Journal of ...

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

Morningstar brands and products Company Portfolio ...

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitLONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company ...